Head and Neck Cancer Trial, Recruiting (NCT06380686)

Head and Neck Cancer Trial, Recruiting NCT06380686 Sponsor: AIO-Studien-gGmbH Condition: Head and Neck Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06380686 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Head And Neck Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who are able to understand the trial information and are willing to sign a written consent form
People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck — specifically in the oral cavity (mouth), oropharynx (middle throat), hypopharynx (lower throat), or larynx (voice box), confirmed through a tissue or cell sample
People whose cancer cannot be treated with the aim of a cure, and who are receiving palliative (comfort-focused) systemic treatment or best supportive care (care focused on managing symptoms)
People who give their consent to join no later than four weeks after starting their first palliative systemic treatment — or, for those receiving best supportive care only, no later than six weeks after being diagnosed with or found to have returning or spread (metastatic) disease

Who may not be able to join:

No exclusion criteria have been listed for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Victor Grünwald, Prof. Dr., Universitätsklinikum Essen

Phone: +49 (0)30 814534431

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06380686

Sponsor: AIO-Studien-gGmbH

Phase: Not Applicable

Status: Recruiting

Condition: Head and Neck Cancer

Trial contact: +49 (0)30 814534431

More information: https://clinicaltrials.gov/study/NCT06380686

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who are able to understand the trial information and are willing to sign a written consent form
People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck — specifically in the oral cavity (mouth), oropharynx (middle throat), hypopharynx (lower throat), or larynx (voice box), confirmed through a tissue or cell sample
People whose cancer cannot be treated with the aim of a cure, and who are receiving palliative (comfort-focused) systemic treatment or best supportive care (care focused on managing symptoms)
People who give their consent to join no later than four weeks after starting their first palliative systemic treatment — or, for those receiving best supportive care only, no later than six weeks after being diagnosed with or found to have returning or spread (metastatic) disease

Who may not be able to join:

No exclusion criteria have been listed for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AIO-Studien-gGmbH

Registry

ClinicalTrials.gov

Start date

7 November 2024

Est. completion

1 November 2029

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Sociodemographic factors; Treatments; Response rates; Treatment decision; Progression-free survival; Time-to-treatment-failure; Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov